title: Erythrokeratodermia variabilis et progressiva.
abstract: Erythrokeratodermia variabilis et progressiva (EKVP) is a rare inherited skin disease characterized by fixed hyperkeratotic plaques and transient erythematous patches. EKVP is most often transmitted in an autosomal dominant manner. Causal mutations were found in the GJB3, GJB4 and GJA1 genes encoding connexins 31, 30.3 and 43, respectively. Approximately 50% of affected individuals develop palmoplantar keratoderma. Connexins are components of gap junctions, which are intercellular channels that are found in almost all tissues including the skin. Treatment of EKVP usually involves use of topical keratolytics and emollients resulting in some improvement in hyperkeratosis. Low-dose systemic retinoid may be beneficial. Novel therapies targeting connexin hemichannels and gap junctions may become available in the future.
authors.affiliation: Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan.
authors.forename: Akemi
authors.initials: A
authors.lastname: Ishida-Yamamoto
mesh_terms: D017630:Connexins / Q000737:chemistry / Q000235:genetics; D056266:Erythrokeratodermia Variabilis / Q000235:genetics / Q000473:pathology / Q000628:therapy; D017629:Gap Junctions / Q000473:pathology; D006801:Humans; D007641:Keratolytic Agents / Q000627:therapeutic use; D009154:Mutation; D000072417:Protein Domains
chemical_list: D017630:Connexins; D007641:Keratolytic Agents
keywords: connexin 30.3; connexin 31; connexin 43; connexins; gap junctions